The use of bicyclol in the treatment of severe liver fibrosis: experimental rationale
Aim. To evaluate the antifibrotic effect of bicyclol with promising clinical effects on diffuse parenchymal liver diseases.Materials and methods: We have included 40 adult male Wistar rats (weight, 180 to 200g) with experimentally inducted toxic F3 stage liver fibrosis. Control group consisted of 16...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Journal Infectology
2021-01-01
|
| Series: | Журнал инфектологии |
| Subjects: | |
| Online Access: | https://journal.niidi.ru/jofin/article/view/1149 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850043487674695680 |
|---|---|
| author | K. V. Zhdanov A. V. Saulevich K. V. Kozlov S. M. Zakharenko V. S. Sukachev V. E. Karev Yu. F. Zakharkiv I. V. Potekhin R. M. Mukhtarov K. V. Kasianenko S. S. Karyakin M. G. Chernenok |
| author_facet | K. V. Zhdanov A. V. Saulevich K. V. Kozlov S. M. Zakharenko V. S. Sukachev V. E. Karev Yu. F. Zakharkiv I. V. Potekhin R. M. Mukhtarov K. V. Kasianenko S. S. Karyakin M. G. Chernenok |
| author_sort | K. V. Zhdanov |
| collection | DOAJ |
| description | Aim. To evaluate the antifibrotic effect of bicyclol with promising clinical effects on diffuse parenchymal liver diseases.Materials and methods: We have included 40 adult male Wistar rats (weight, 180 to 200g) with experimentally inducted toxic F3 stage liver fibrosis. Control group consisted of 16 rats that received standart chow, experimental group of 24 rats also received 30-day bicyclol supply. To evaluate the results we used histological, biochemical, molecular genetic and statistical methods.Results. In experimental group interlobular fibrosis was maintained in 4,16% (p<0,001) of cases after the end of the therapy, stromal fibrosis of portal tracts was observed in 62,5% (p<0,001) of cases. Periportal fibrosis detection rate in experimental group was 66,7% (p<0,001). Rats from experimental group showed regression of liver fibrosis to F1- F2 stage in 16,6% (METAVIR) whereas control group had F3 stage liver fibrosis in 62,5% (p <0,05). Statistically significant increase in ALT activity and decreased total protein levels in control group were observed. No changes in gut microbiome profile in experimental animals were found.Conclusion. Use of bicyclol led to pronounced suppression of liver fibrotic changes in laboratory animals and temporary decreased serum ALT level. Our study showed no link between therapeutic effects of the drug and gut microbiome status. |
| format | Article |
| id | doaj-art-b103cdc8d7144b8980d07fffde85be8e |
| institution | DOAJ |
| issn | 2072-6732 |
| language | Russian |
| publishDate | 2021-01-01 |
| publisher | Journal Infectology |
| record_format | Article |
| series | Журнал инфектологии |
| spelling | doaj-art-b103cdc8d7144b8980d07fffde85be8e2025-08-20T02:55:13ZrusJournal InfectologyЖурнал инфектологии2072-67322021-01-011259310010.22625/2072-6732-2020-12-5-93-100871The use of bicyclol in the treatment of severe liver fibrosis: experimental rationaleK. V. Zhdanov0A. V. Saulevich1K. V. Kozlov2S. M. Zakharenko3V. S. Sukachev4V. E. Karev5Yu. F. Zakharkiv6I. V. Potekhin7R. M. Mukhtarov8K. V. Kasianenko9S. S. Karyakin10M. G. Chernenok11Military Medical Аcademy named after S.M. KirovMilitary Medical Аcademy named after S.M. KirovMilitary Medical Аcademy named after S.M. KirovMilitary Medical Аcademy named after S.M. KirovMilitary Medical Аcademy named after S.M. KirovPediatric Research and Clinical Center for Infectious DiseaseMilitary Medical Аcademy named after S.M. KirovMilitary Medical Аcademy named after S.M. KirovMilitary Medical Аcademy named after S.M. KirovMilitary Medical Аcademy named after S.M. KirovMilitary Medical Аcademy named after S.M. KirovMilitary Medical Аcademy named after S.M. KirovAim. To evaluate the antifibrotic effect of bicyclol with promising clinical effects on diffuse parenchymal liver diseases.Materials and methods: We have included 40 adult male Wistar rats (weight, 180 to 200g) with experimentally inducted toxic F3 stage liver fibrosis. Control group consisted of 16 rats that received standart chow, experimental group of 24 rats also received 30-day bicyclol supply. To evaluate the results we used histological, biochemical, molecular genetic and statistical methods.Results. In experimental group interlobular fibrosis was maintained in 4,16% (p<0,001) of cases after the end of the therapy, stromal fibrosis of portal tracts was observed in 62,5% (p<0,001) of cases. Periportal fibrosis detection rate in experimental group was 66,7% (p<0,001). Rats from experimental group showed regression of liver fibrosis to F1- F2 stage in 16,6% (METAVIR) whereas control group had F3 stage liver fibrosis in 62,5% (p <0,05). Statistically significant increase in ALT activity and decreased total protein levels in control group were observed. No changes in gut microbiome profile in experimental animals were found.Conclusion. Use of bicyclol led to pronounced suppression of liver fibrotic changes in laboratory animals and temporary decreased serum ALT level. Our study showed no link between therapeutic effects of the drug and gut microbiome status.https://journal.niidi.ru/jofin/article/view/1149fibrosis inductionantifibroticbicyclolexperimentliver biopsy |
| spellingShingle | K. V. Zhdanov A. V. Saulevich K. V. Kozlov S. M. Zakharenko V. S. Sukachev V. E. Karev Yu. F. Zakharkiv I. V. Potekhin R. M. Mukhtarov K. V. Kasianenko S. S. Karyakin M. G. Chernenok The use of bicyclol in the treatment of severe liver fibrosis: experimental rationale Журнал инфектологии fibrosis induction antifibrotic bicyclol experiment liver biopsy |
| title | The use of bicyclol in the treatment of severe liver fibrosis: experimental rationale |
| title_full | The use of bicyclol in the treatment of severe liver fibrosis: experimental rationale |
| title_fullStr | The use of bicyclol in the treatment of severe liver fibrosis: experimental rationale |
| title_full_unstemmed | The use of bicyclol in the treatment of severe liver fibrosis: experimental rationale |
| title_short | The use of bicyclol in the treatment of severe liver fibrosis: experimental rationale |
| title_sort | use of bicyclol in the treatment of severe liver fibrosis experimental rationale |
| topic | fibrosis induction antifibrotic bicyclol experiment liver biopsy |
| url | https://journal.niidi.ru/jofin/article/view/1149 |
| work_keys_str_mv | AT kvzhdanov theuseofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT avsaulevich theuseofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT kvkozlov theuseofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT smzakharenko theuseofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT vssukachev theuseofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT vekarev theuseofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT yufzakharkiv theuseofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT ivpotekhin theuseofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT rmmukhtarov theuseofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT kvkasianenko theuseofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT sskaryakin theuseofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT mgchernenok theuseofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT kvzhdanov useofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT avsaulevich useofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT kvkozlov useofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT smzakharenko useofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT vssukachev useofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT vekarev useofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT yufzakharkiv useofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT ivpotekhin useofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT rmmukhtarov useofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT kvkasianenko useofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT sskaryakin useofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale AT mgchernenok useofbicyclolinthetreatmentofsevereliverfibrosisexperimentalrationale |